moatshark My

All holdings

Elanco Animal Health

ELAN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$1.7bn
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$24.61
+2.8% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+1.8%Q3 ’24
-17.6%Q4 ’24
-13.3%Q1 ’25
+36.0%Q2 ’25
+41.0%Q3 ’25
+12.4%Q4 ’25
+5.7%Q1 ’26
+2.8%Q2 ’26
Q3 ’24: +1.8%; Q4 ’24: -17.6%; Q1 ’25: -13.3%; Q2 ’25: +36.0%; Q3 ’25: +41.0%; Q4 ’25: +12.4%; Q1 ’26: +5.7%; Q2 ’26: +2.8%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Elanco Animal Health.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Elanco Animal Health
Dodge & Cox0.9%$1.7bn$1.7bnTrimmed -2.2%20 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Elanco Animal Health
Bought or soldFiling
15 Oct 2026Bettington Timothy JSEE REMARKS▼ Sold4,350$23.00$100kForm 4
20 Aug 2026Kurzius Lawrence ErikDirector▲ Bought40,000$23.40$936kForm 4
18 Aug 2026O'Neill ShivGC AND CORP SEC▲ Bought3,998$23.58$94kForm 4
12 Aug 2026Harrington Michael JDirector▲ Bought5,000$21.82$109kForm 4
7 Aug 2026Herendeen PaulDirector▲ Bought10,000$23.68$237kForm 4
7 Aug 2026Vanhimbergen Robert MEVP and CFO▲ Bought4,200$23.08$97kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Financial year ends
31 December
Shares outstanding
500m at 3 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$2.9bn2016
$2.9bn2017
$3.1bn2018
$3.1bn2019
$3.3bn2020
$4.8bn2021
$4.4bn2022
$4.4bn2023
$4.4bn2024
$4.7bn2025
2016: $2.9bn; 2017: $2.9bn; 2018: $3.1bn; 2019: $3.1bn; 2020: $3.3bn; 2021: $4.8bn; 2022: $4.4bn; 2023: $4.4bn; 2024: $4.4bn; 2025: $4.7bn
Elanco Animal Health revenue and net income by year
YearRevenueNet income
2025$4.7bn−$232m
2024$4.4bn$338m
2023$4.4bn−$1.2bn
2022$4.4bn−$78.0m
2021$4.8bn−$483m
2020$3.3bn−$574m
2019$3.1bn$68.0m
2018$3.1bn$86.5m
2017$2.9bn−$311m
2016$2.9bn−$47.9m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Elanco Animal Health, from their latest N-PORT filings.

Funds holding Elanco Animal Health
Dodge & Cox Global Stock FundDodge & Cox0.5%$59.9m30 Jun 2026